Sounds like you’re blaming XOMA’s current management for the disclosures that XOMA’s former management did not make about AEs in the Gevokicumab diabetes trials.
No! I am claiming that past management was typical biotech. They intentionally didn't talk about unfavorable results - and in the case of excess infection risk... they didn't provide data. Had you been watching Xoma then you would have drawn the obvious inference.
I suppose current management could release those data, but it’s not typical for a biotech company to focus investors’ attention—even indirectly—on defunct programs such as Gevokizumab for diabetes.
No. In this case they are the ones that brought up the topic (as they should IMO). Why in the world would you talk the topic based upon theory when you have real world data. Unless the real world data was counter to the theory.
Market Data 
Markets 
AI
